Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.

CONCLUSIONS: Safinamide, at a clinically relevant dose, optimizes the effect of l-DOPA therapy in experimental PD reducing SPNs excitability and modulating synaptic transmission. Co-administration of safinamide and l-DOPA ameliorates motor deficits.
PMID: 32142791 [PubMed - as supplied by publisher]

Source: Neuropharmacology - March 2, 2020 Category: Drugs & Pharmacology Authors: Sciaccaluga M, Mazzocchetti P, Bastioli G, Ghiglieri V, Cardinale A, Mosci P, Caccia C, Keywood C, Melloni E, Padoani G, Vailati S, Picconi B, Calabresi P, Tozzi A Tags: Neuropharmacology Source Type: research